the collaboration mandate - survey overview
DESCRIPTION
TRANSCRIPT
Copyright © 2013 Quintiles
The Collaboration Mandate
July 2013
Adam IstasThought Leadership Director - Quintiles
2
The Collaboration Mandate
• Objectives> Since 2010 Quintiles has commissioned
independent research to develop and publishThe New Health Report.
• Methodology> 53 Provider executives
- Representing integrated healthcare systems and academic medical centers
- 100% from the US
> 143 Payer executives- 68 from managed care organizations in the US- 75 from government payer organizations in Europe
» (France, Germany, Italy, Spain, United Kingdom)
> 102 Biopharmaceutical executives- Vice-president level and above - At least 25% from outside the U.S.
Objectives & Methodology
Biopharma
US Payers
EU Payers
Providers
102
68
75
53
3
The Collaboration MandateKey Findings
Payers, providers and biopharma agree that they need to be better aligned with other stakeholders in the healthcare industry, yet they have struggled to achieve this goal.
Only 16-19% of survey respondents said they were mostly aligned with other stakeholders, while one-fourth said they are not very or not at all aligned.
4
The Collaboration MandateKey Findings
All three groups rated improved health outcomes and innovation among the greatest benefits of cross-stakeholder initiatives.
Payers are also interested in reducing the cost of care, providers seek improved care experiences and biopharma wants to accelerate the rate at which new therapies get to market.
5
The Collaboration MandateKey Findings
More than 70% of all stakeholders believe transparency around data sources and information-sharing across stakeholders is very important or critically important to the success of an interoperable healthcare system.
Their biggest obstacles to adopting a systems-oriented approach are lack of trust, poor financial incentives and varying definitions of value.
6
The Collaboration MandateKey Findings
At least three out of four survey participants believe it is very important or extremely important for data sources collected by different stakeholders to be linked together to better inform decisions.
However, more than half feel they have neither the tools nor the expertise to optimize use of these data sets.
7
Implications / Recommendations
The report outlines recommendations for biopharma to improve their collaboration to benefit business and improve patient outcomes.
• Diversify partnerships to drive innovation. Seek opportunities to partner with stakeholders from across the healthcare continuum. Ideally these opportunities will stretch comfort zones beyond the traditional regulatory partnerships, with the promise of innovation in exchange for transparency and a willingness to work collaboratively for mutual benefit.
• Build the roadmap together. Define success and then work in concert with partners to build the roadmap to get there. When collaboration has a destination, every individual heads in the same direction.
• Foster—and use—feedback. Regularly review results through formal check points and feedback channels with a focus on how to continually optimize design based on system feedback. Ensure stakeholders stay connected to the team and foster a culture of trust by communicating results and feedback regularly across the stakeholder community.
8
Contact Information
Mari Mansfield, Corporate Communications
O: +1 919 998 2639
M: +1 919 259 3298
Laura Wilson, Corporate Communications - Europe
O: +44 118 450 8392
M: +44 7854 173 106
> http://www.quintiles.com/collaborationmandate
For additional information about The Collaboration Mandate